Physician profile
David Hardy
NPI 1083149397
$5,615.97
in general payments reported to CMS, 2019-2025
37 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.74 · 2022: $1,441 · 2023: $2,400 · 2024: $1,329 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,111.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $984.25 | 2022-2025 | |
| Novo Nordisk INC | $691.27 | 2022-2024 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $651.93 | 2022-2025 | |
| Glaxosmithkline, LLC. | $402.69 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $357.22 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $274.35 | 2022-2024 | |
| Astellas Pharma US INC | $199.87 | 2023-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $172.59 | 2022-2024 | Mounjaro, Trulicity, Zepbound |
| Merck Sharp & Dohme LLC | $168.51 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $152.41 | 2023-2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $148.44 | 2022-2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $128.81 | 2022-2024 | Breztri, Farxiga |
| Baxter Healthcare | $112.93 | 2023-2025 | Perclot, Biosurgery - Guard |
| Amgen INC. | $103.52 | 2022-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.33 | 2022-2025 | Ofev, Jardiance |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $97.45 | 2022-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $84.53 | 2023-2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.40 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $78.33 | 2023-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $77.94 | 2022-2024 | Ajovy |
| Dexcom, INC. | $74.52 | 2022-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $69.35 | 2022-2024 | Xarelto |
| W. L. Gore & Associates, INC. | $58.15 | 2021-2023 | Gore Viabahn Endoprosthesis With Heparin, Gore Viabahn Vbx Balloon Expandable Endo |
| Atricure, INC. | $51.27 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $44.52 | 2022-2023 | Seglentis, Livalo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.41 | 2022-2023 | Xifaxan |
| Mylan Specialty L.P. | $36.74 | 2022-2023 | Yupelri |
| Corium, LLC | $35.86 | 2023 | Adlarity |
| Acella Pharmaceuticals, LLC | $21.99 | 2024 | NP Thyroid 60 |
| Grt US Holding, INC. | $20.80 | 2022 | |
| Axsome Therapeutics, INC. | $16.34 | 2024 | Auvelity |
| Amarin Pharma, INC. | $15.36 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.68 | 2022 | |
| Sunovion Pharmaceuticals INC. | $13.62 | 2022 | |
| Nevro Corp. | $12.43 | 2022 | |
| Horizon Therapeutics Plc | $12.18 | 2022 | |
| Dynavax Technologies Corporation | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.